The problem
Glioblastoma is an aggressive brain tumor; MIT News notes a little more than 10,000 cases are diagnosed in the US each year and patients survive 12 to 15 months on average. Surgeons struggle to remove every cancer cell, so tumors often recur. Implantable wafers and gels can release drugs locally, but they rely on passive diffusion.
What MIT built
Researchers led by Canan Dagdeviren created LUCID, the Long-term Ultrasound-enhanced Convective Injection Device, described in a paper in the journal Device. A drug-delivery cannula is 3D printed directly onto an array of 24 miniature ultrasound transducers in a flexible implant as thin as cardstock. Ultrasound generated at the needle tip helps molecules diffuse farther and temporarily increases blood-brain barrier permeability.
The reservoir holds about 100 microliters, infusion is driven by a passive osmotic pump, and the ultrasound can be controlled wirelessly over Bluetooth. A small battery recharges wirelessly.
Results so far
In a gel-like tissue phantom, ultrasound-aided delivery spread molecules much farther than delivery without ultrasound. In mice, an MRI contrast agent spread further through the brain when the array was active. Lead author Sarah Ornellas says local, programmable enhancement could reduce toxicity in non-target organs.
Caveats
The results are from tissue models and mice, using a contrast agent rather than cancer drugs. Clinical use would require much more testing; MIT frames the device as something researchers hope could help prevent recurrence.
Practical takeaways
- This is preclinical research, not a treatment.
- Programmable, wireless control is the feature to watch in future studies.
- Look for tests with therapeutic drugs and larger animals.
Bottom line
LUCID shows how combining delivery and ultrasound in one thin implant could extend how far a drug travels. Human benefit remains unproven.